^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | CC-115 (mTOR inhibitor, DNA PK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of mTORC1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Published date:
06/23/2022
Excerpt:
We demonstrate that CC-115 synergizes with carboplatin in 6 of 14 NSCLC cell lines, primarily PIK3CA-mutant LUSC. Synergy was more common in cell lines that had decreased basal levels of activated AKT and DNA-PK, evidenced by reduced P-S473-AKT, P-Th308-AKT, and P-S2056-DNA-PKcs. CC-115 sensitized LUSC to carboplatin by inhibiting chemotherapy-induced AKT activation and maintaining apoptosis, particularly in PIK3CA-mutant cells lacking wild-type TP53.
Secondary therapy:
carboplatin
DOI:
10.1158/1535-7163.MCT-22-0053
